Boston Scientific adds $4.0 billion to buyback and appoints two new directors
Boston Scientific expanded its board from ten to twelve members and appointed Catherine R. Smith and Christophe P. Weber as directors, effective February 18, 2026. The board also approved a $4.0 billion increase to its stock repurchase authorization, bringing the total available to $5.0 billion, all of which remained available as of the filing date.
Key points
- Board increased from ten to twelve members on February 18, 2026; Catherine R. Smith and Christophe P. Weber appointed directors effective that date.
- Smith joins the Audit and Nominating and Governance committees; Weber joins the Executive Compensation and Human Resources and Risk, Science and Technology committees, effective February 23, 2026.
- On February 18, 2026, the board approved an additional $4.0 billion repurchase authorization, for a total of $5.0 billion.
- Each new director will receive prorated annual compensation, including a cash retainer of about $24,663 and an equity award of about $42,420, with shares granted March 2, 2026.
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.